The synthesis of new 5-cyano-1,1-disubstituted phthalans having aromatic and aminoalkyl groups at C-1 position of phthalan ring and their biological evaluation are described. Most compounds exhibited comparable ejaculation-retarding effects to citalopram. Of these compounds, 3a, e showed excellent efficacy in delaying ejaculation.
Introduction
Premature ejaculation (PE) 1 is one of the most prevalent male sexual dysfunctions, with a prevalence rate of 30%, 3 times greater than that seen for erectile dysfunction.
2 Nonpharmacologically, behavioral methods (e.g. stop-start technique, 3 squeeze technique 4 ) have been used for the treatment of PE. However they are difficult for patients to execute. Several pharmacologic and herbal treatments for PE are in use today. However, because none of these agents has yet been approved by the US FDA for this indication, they are being used investigationally or off label. Pharmacological treatments have included the use of topical anesthetics, 5 tricyclic antidepressants (TCAs), 6 and selective serotonin reuptake inhibitors (SSRIs) . 7 The use of topical anesthetics can produce the problem of local irritation and burning pain, and TCAs such as clomipramine have a high incidence of adverse effects. The introduction of the SSRIs, which have a benign adverse effect profile compared with TCAs, provided another option and SSRIs (paroxetine, 8,10,12(a) fluoxetine, 9, 10 fluvoxamine, 10 sertraline, 11,8(d) ,9(c),10 citalopram, 12 dapoxetine 13 ) are reported to be effective for treating PE.
Citalopram is a potent and highly SSRIs antidepressant without much cardiotoxic, anticholinergenic and sedating effects. It was suggested that citalopram's selectivity for the serotonergic system over other systems would cause considerable delay ejaculation.
Based on the importance of earlier findings, we carried out the introduction of aromatics and aminoalkyl substitutes into 5-cyanophthalan nucleus in order to improve the activity for PE and safety like citalopram ( Fig. 1 ) and the products showed good efficacy with delaying premature ejaculation.
In this paper, we wish to describe synthesis of novel 5-cyanophthalans having aromatic and aminoalkyl group as C-1 side chains and biological evaluation for the compounds.
Chemistry
At first, we attempted the direct conversion 5-cyanophthalide (2) 14 into 3-(hydroxymethyl)-4-(1,1-disubstituted hydroxymethyl)benzonitril using the two Grignard's reagents (ArMgBr then aminoalkyl MgBr) described Bogeso 15 however these conditions resulted in low yields (< 10%). So, 1-aryl-5-cyanophthalane 5a-f, key intermediates, was prepared by the sequence outlined in Scheme 1. 16 The diol 4a-f were prepared by Grignard's reaction of ArMgBr with 5-cyanophthalide (2) and subsequent reduction with NaBH 4 . The cyclization of diol 4a-f with H 3 PO 4 in EtOAc afforded 1-aryl-5-cyanophthalane 5a-f.
Introduction of the ethyl or propyl chain was performed by alkylation of phthalan 5a-f with the corresponding bromo TBS protected alchol 6 in the presence of NaH to yield the 1,1-disubstituted phtalan 7a-f (Scheme 2). Deprotection of 7a-f with tetrabutylammonium fluoride in THF provided the alcohol 8a-f. Mesylation of hydroxyl group of 8a-f followed by conversion of the resulting mesylate 9a-f with amines such as pyrazole, imidazole, and dimethylamine in the presence of K 2 CO 3 gave amines, which upon saltation with HCl provided the desired target molecules 1 and 2.
Selected compounds were performed trans saltation and chiral resolution by the sequence of reactions shown in Scheme 3. The salt exchange from HCl to oxalic acid to give oxalate 3a-e gave the stable solids compared with HCl amorphous salts. The preparation of the single enantiomer 3c, d carried out by the stereoselective crystallization of the diastereomeric salts of the 3b with (−)/(+)-di-p-toloyltartaric acid. 
Biological Properties
The title 5-cyano-1,1-disubstituted phthalans prepared above were evaluated for the efficacy on ejaculatory response by PCA (p-chloroamphetamine) induced ejaculation model 18 as shown in Table 1 . Some compounds exhibited more potent activity for delaying ejaculation than control. With the exception of 2f, 5-cyanophthalans having 3-dimethylaminopropyl group 2c, i, l, o, r showed more potent delaying activity than those bearing 2-aminoethyl group. 2-Thienyl derivatives 2q, r were as active as citalopram HCl (2l). The pyrazole derivatives showed lower activity than others. Among the compounds prepared, based on their efficacy on ejaculatory response, 3 compounds 2i, q, r were selected and performed trans saltation/chiral resolution (3a-e) for further evaluation. Table 2 shows the efficacy on ejaculatory response of selected compounds 3a-e together with citalopram as reference compound in a range of 50, 25, and 12.5 mg/kg dose. They showed excellent efficacy and dose-dependent response. Especially, the compounds 3a, e had comparable activity to citalopram in delaying ejaculation at all dose range. The enantiomer 3c showed more potent activity than (−)-form 3d and was as active as racemic mixture 3b.
In summary, the title 5-cyano-1,1-disubstituted phthalans bearing aromatic and aminoalkyl groups as C-1 side chains exhibited potent efficacy in delaying ejaculation by PCA induced ejaculation model in rat. In these series, 3a, e exhibited excellent efficacy in delaying ejaculation. Scheme 3. Reagents and Reaction conditions: (i) aq. NaOH, THF; (ii) oxalic acid, EtOH (65% for 3a, 81% for 3b, 91% for 1e, 2 steps);
NaOH, THF, rt, 0.5 h, then oxalic acid, EtOH (34% for 3c, 33% for 3d, 2 steps).
Experimental PCA (p-chloroamphetamine) induced ejaculation model assay. Male Wistar rats, 240-260 g, were used and anesthetized with ketamine 30 mg/kg, xylazine 8 mg/kg, and acepromazine 0.04 mg/kg (I.M.). Each compound was suspended in 1% HPMC solution (50, 25 and 12.5 mg/kg) and given orally in a volume of 5 mL/kg. The administration of compound and anesthesia were performed 80, 20 min before the administration of PCA (5 mg/mL saline/kg, i.p.). The ejaculatory response -rhythmic contraction of blubocavernous muscle and ejaculation of ejaculate -was observed for 30 min after PCA administration. The statistical significance of differences between groups in ejaculation ratio (the number of rats ejaculated/total rats tested) was analyzed with Fisher exact test and latency (time to ejaculation after PCA injection) was expressed as mean ± SD (not analyzed).
1-(Thien-2-yl)-1,3-dihydro-5-isobenzofurancarbonitrile (5f). To a solution of 5-cyanophthalide (2) (50.64 g, 318.18 mmol) in anhydrous CH 2 Cl 2 (500 mL) was added dropwise 2-thienyl magnesium bromide (1 M in THF, 350 mL, 350 .0 mmol) at −78 o C under nitrogen atmosphere. The mixture was warmed to room temperature and stirred for 16 h. The reaction mixture was quenched with 20% aq. NH 4 Cl and the organic layer was diluted with MeOH (100 mL). NaBH 4 (24.08 g, 636.42 mmol) was slowly added to the mixture at 0 o C and stirred for 3 h at room temperature. The mixture was quenched with 20% aq. NH 4 Cl and washed with brine. The organic layer was concentrated in vacuo to give diol compound 4f as a yellow oil. To a solution of a compound 4f in EtOAc (500 mL) was added 85% H 3 PO 4 (500 mL) at room temperature and heated to 80 o C. After being stirred for 3 h at the same temperature, the mixture was washed with water, sat. NaHCO 3 and brine. The organic layer was dried over anhydrous MgSO 4 and concentrated in vacuo. The residue was treated with 2-propanol to provide a solid. This solid was filtered and washed with n-hexane to give 1-(thien-2yl)-1,3-dihydro-5-isobenzofurancarbonitrile (5f) (42.71 g, 59%, 3 steps) as a pale brown solid; Ejaculation ratio (the number of rats ejaculated/total rats tested, n/n), vehicle (7/7). Ejaculation ratio (the number of rats ejaculated/total rats tested, n/n). 1-(3-tert-Butyldimethylsilyloxypropyl)-1-(thien-2-yl)-1,3-dihydro-5-isobenzofurancarbonitrile (7f). To a solution of 5-cyanophthalne 5f (42.70 g, 187.87 mmol) in DMSO (400 mL) was added NaH (60% in mineral oil, 9.02 g, 225.44 mmol) and stirred for 0.5 h at room temperature. 3-Bromo-1-(tetr-butyldimethylsilyl)propanol (6) (71.37 g, 281.18 mmol) was added to the mixture at the same temperature and heated to 80 o C. After being stirred for 24 h, the mixture was diluted with EtOAc and washed with water and brine. The organic layer was dried over anhydrous MgSO 4 and concentrated in vacuo. The residue was purified by silica gel column chromatography (n-hexane/EtOAc = 4:1) to give coupling compound 7f (60.28 g, 80%) as a yellow oil; 1-(3-Hydroxypropyl)-1-(thien-2-yl)-1,3-dihydro-5-isobenzofurancarbonitrile (8f). To a solution of compound 7f (60.28 g, 150.84 mmol) in THF (500 mL) was added tetrabutylammonium fluoride (1 M in THF, 226.3 mL, 226.3 mmol) at room temperature. After being stirred for 2 h, the mixture was diluted with EtOAc and washed with water and brine. The organic layer was dried over anhydrous MgSO 4 and concentrated in vacuo. The residue was purified by silica gel column chromatography (n-hexane/EtOAc = 1:1) to give alcohol 8f (29.29 g, 68%) as a pale yellow oil; 1-{3-(Imidazol-1-yl)propyl}-1-(thien-2-yl) . To a solution of mesylate 9f (18.65 g, 51.31 mmol) in DMF (200 mL) were added K 2 CO 3 (28.36 g, 205.24 mmol) and imidazole (13.97 g, 205. 24 mmol) at room temperature and heated to 80 o C. After being stirred for 24 h, the mixture was diluted with EtOAc and washed with water and brine. The organic layer was dried over anhydrous MgSO 4 and concentrated in vacuo. The residue was purified by silica gel column chromatography (CH 2 Cl 2 /MeOH = 9:1) to give amine compound (9.04 g, 58%) as a pale yellow oil; 6, 148.0, 139.2, 134.9, 132.0, 127.3, 125.7, 124.8, 122.8, 122.7, 121.7, 119.5, 118.5, 110.7, 89.1, 71.4, 48.2, 37.3, 24 .8.
1-{3-(Imidazol-1-yl)propyl}-1-(thien-2-yl)-1,3-dihydro-5-isobenzofurancarbonitrile oxalic acid (3b). To a solution of HCl salt 2q (6.95 g, 18.69 mmol) in THF (140 mL) was added 2 N-NaOH (11.2 mL, 22.4 mmol) at 0 o C and stirred for 0.5 h. The reaction mixture was concentrated in vacuo. The residue was dissolved in EtOAc and washed with water and brine. The organic layer was dried over anhydrous MgSO 4 and treated with charcoal. The solution was filtered on celite pad and the filtrate was evaporated in vacuo to give free amine (5.72 g, 91%) as a pale yellow oil. The solution of free amine in EtOH (70 mL) was added oxalic acid (2.36 g, 18.76 mmol) at room temperature and stirred for 0.5 h. The mixture was cooled to 0 o C and stirred for 1 h. The white precipitate was filtered and washed with n-hexane to give 3b (6.46 g, 89%) as white solid: mp = 160. 7, 148.7, 148.1, 139.2, 136.0, 132.0, 127.3, 125.7, 124.8, 123.8, 122.7, 122.6, 120.4, 118.5, 110.7, 89.2, 71.4, 47.0, 37.6, 25.3. (+)-1-{3-(Imidazol-1-yl)propyl}-1-(thien-2-yl)-1,3-dihydro-5-isobenzofurancarbonitrile oxalic acid (3c). To a solution of 1-{3-(imidazol-1-yl)propyl}-1-(thien-2-yl)-1,3-dihydro-5-isobenzofurancarbo-nitrile (6.97 g, 20.8 mmol) in CH 3 CN (85 mL) was added D-(−)-di-p-toluoyltartaric acid (8.03 g, 20.8 mmol) at room temperature. After being stirred for 20 min, the mixture was heated to 60 o C and stirred for 1 h. MeOH (6.8 mL) was added to the mixture at the same temperature and stirred for 1 h. The white solid was filtered and dried to give DPPTA salt (5.48 g, 34%). To a solution of (+)-1-{3-(Imidazol-1-yl)propyl}-1-(thien-2-yl)-1,3-dihydro-5-isobenzofurancarbonitrile D-(−)-DPPTA salt (5.48 g, 7.85 mmol) in THF (100 mL) was added 1 N NaOH (10 mL, 10 mmol) at room temperature and stirred for 0.5 h. The mixture was concentrated in vacuo. The residue was treated with EtOAc and water. The organic layer was dried over anhydrous MgSO 4 and evaporated under reduced pressure to give free amine (1.41 g, 54%) as a pale yellow oil. The oil was dissolved with EtOH (14 mL) and oxalic acid (0.58 g, 4.6 mmol) was added to the mixture. After being stirred for 1 h at 0 o C, the precipitate was filtered and washed with nhexane to give oxalic acid salt 3c (1.45 g, 81%) as a white solid: [α] = + 6.02 deg (Na 589 nm, 24.9 o C, MeOH, c = 0.1).
